Proqr Therapeutics N.v Stock News

ProQR Therapeutics N.V. (NASDAQ: PRQR) has decided to prioritize the development of genetic eye disease candidates and the Axiomer RNA base-editing technology platform.

Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now?

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tra

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of t

ProQR Therapeutics N.V. (NASDAQ:PRQR) with the stream of 3.15% also noticed, India Enservco Corporation (AMEX:ENSV) encountered a rapid change of 85.19% in the last hour of Monday’s trading session. ProQR … The post Glistering Stock: ProQR Therapeutics N.V. (NASDAQ:PRQR), Enservco Corporation (AMEX:ENSV) appeared first on Stocks Equity .

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of t

ProQR (PRQR) delivered earnings and revenue surprises of -15.38% and 69.50%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

During the last session, ProQR Therapeutics N.V. (NASDAQ:PRQR)’s traded shares were 3.38 million, with the beta value of the company hitting 0.57. At the end of the trading day, the stock’s price was $1.20, reflecting an intraday loss of -1.64% or -$0.02. The 52-week high for the PRQR share is $9.46, that puts it down … Is ProQR Therapeutics N.V. (NASDAQ: PRQR) Still A Loss Stock Despite Being Down -85.02% YTD? Read More »

ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the last trading session, 8.62 million shares of the ProQR Therapeutics N.V. (NASDAQ:PRQR) were traded, and its beta was 0.57. Most recently the company’s share price was $1.25, and it changed around -$0.14 or -10.07% from the last close, which brings the market valuation of the company to $360.89M. PRQR currently trades at a … Why ProQR Therapeutics N.V. (NASDAQ: PRQR) Stock Should Not Be Discarded By Investors In 2022 Read More »

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.

ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.

Citi has downgraded ProQR Therapeutics <> to Neutral from Buy after the clinical-stage biotech company reported that its pivotal Phase 2/3 study for RNA therapy sepofarsen did

Analysts are notably more bearish on the company following unhappy news about its leading drug candidate.